Breast cancer remains a leading cause of cancer-related death for women, despite therapeutic advances. Current treatments involve surgery and hormone therapy. However, these treatments can lead to side effects like osteoporosis and sexual dysfunction. Recently, researchers have developed a promising small-molecule drug called ErSO-TFPy.
So far, the drug has shown remarkable results in mice, completely eliminating small tumors and significantly shrinking large tumors with a single dose. The drug targets estrogen receptor-positive (ER+) breast cancer cells with high selectivity and minimal side effects, offering hope for a more effective treatment approach. If further testing confirms its safety and efficacy in humans, ErSO-TFPy could potentially transform breast cancer treatment by providing a more targeted and less invasive therapeutic option.